Analysing the blood Methyl Malonic Acid and blood Vitamin B12 levels in patients with mouth early stage cancers
Not Applicable
- Conditions
- Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx
- Registration Number
- CTRI/2022/08/044847
- Lead Sponsor
- Rajiv Gandhi University of Health Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
The study consists of 2 groups within the age range of 20 to 60 years. Group A: 26 subjects of Oral Potentially Malignant Disorders
Group B: 26 subjects of healthy controls
Patients will be informed about the study and consent will be obtained.
The subjects will be collected by Simple random sampling method.
Subjects will be diagnosed clinically and confirmed histopathologically as oral potentially malignant disorders will be considered as cases.
Exclusion Criteria
Patients with history of Renal diseases, hematological disorders, liver diseases, gastrointestinal disorders, nutritional deficiencies, prior medication of external supplements and pregnancy will be excluded from the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To obtain a reliable biomarker Serum Methyl Malonic Acid in Oral Potentially Malignant Disorders and to coorelate the marker with serum Vitamin B12 and the stages of progression of the Oral Potentially Malignant disorderTimepoint: To obtain a reliable biomarker <br/ ><br>Serum Methyl Malonic Acid in Oral Potentially Malignant Disorders in first 6 months and to coorelate the marker with serum Vitamin B12 and the stages of progression of the Oral Potentially Malignant disorder in the next 6 months.
- Secondary Outcome Measures
Name Time Method The levels of METHYL Malonic Acid may vary in different stages of Oral Potentially Malignant Disorders and in different lesionsTimepoint: 2 years